Navigation Links
Discuss Early Results of the DIAN Trial at CBI's 6th Annual Alzheimer's Drug Development Summit
Date:8/21/2012

WOBURN, Mass., Aug. 21, 2012 /PRNewswire/ -- CBI recently added John C. Morris M.D., a Friedman Distinguished Professor of Neurology and Director at Knight Research Center of Washington University School of Medicine, to the prestigious speaker roster for CBI's 6th Annual Alzheimer's Drug Development Summit in Philadelphia.

This December 11-12, attendees come together during the session: Future Perspective from the Dominantly Inherited Alzheimer Network (DIAN) (http://www.cbinet.com/conference/workshop/26087/pc12188) to discuss the early results from the trial as well as review key highlights and information:

  • Analyze the importance of the DIAN trial to Alzheimer's clinical trials
  • Discuss the therapies being evaluated in the DIAN trial and study design
  • Understand the initial results of the DIAN clinical trial and forward goals

With a strong agenda filled with expert speakers reflecting on recent clinical trial implications and current research on translational and preventative treatments for Alzheimer's, CBI's 6th Annual Alzheimer's Drug Development Summit offers industry leaders an educational platform to continue the dialogue of research findings and continue to advance towards the prevention and treatment of Alzheimer's disease.

CBI, an Advanstar company, is the leading provider of market-driven, unbiased conferences for the pharmaceutical, biotechnology, medical device and healthcare industries. CBI offers specialized information presented in interactive formats by thought leaders and regulators.

Contact: Kristina Weljkovic
Phone number: 339-298-2285
Email address: Kristina.weljkovic@cbinet.com

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.  


'/>"/>
SOURCE CBI
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. AAAS To Host Live Online Discussion On 2013 U.S. Federal R&D Budget
2. Atlanta LASIK Surgeon Dr. Ashraf Releases YouTube Videos Featuring Patient Testimonials and Discussion of Common Eye Treatments
3. TAKE Solutions Brings Together Leading Experts and TAKE Customers at “Converge 2012” to Discuss Business
4. Expert Meeting Discusses Testing of Oxitec Transgenic Mosquitoes in Panama
5. NIRI San Diego May Meeting: Seasoned IROs Discuss "Tips & Tactics for Establishing and Maintaining A Successful Investor Relations Program"
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
7. Researchers peek at the early evolution of sex chromosomes
8. Butamax Early Adopters Group surpasses capacity targets with addition of Big River; Membership represents 11 production facilities and nearly 900 million gallons of ethanol capacity
9. Corporate Venturing and Early-Stage Financing in the Spotlight at BioTrinity
10. CSL Behring Study Confirms Early Treatment with Berinert® Provides Faster Resolution of Acute Hereditary Angioedema Symptoms
11. Sequenom Announces 2011 Operational Highlights and Early 2012 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)...  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company ... autoimmune diseases, asthma and allergic diseases and cancer, ... and full year ended December 31, 2016 and ... and clinical highlights. "During 2016, we ... by starting five clinical trials across our XmAb ...
(Date:2/28/2017)... ... February 28, 2017 , ... FireflySci is a small cuvette manufacturer ... late 2014, FFS had a mission to bring affordable and quality lab equipment to ... product that gives a lab everything needed to get started with using cuvettes. , ...
(Date:2/28/2017)... ... February 28, 2017 , ... ACEA Biosciences, a pioneer in cell analysis instrumentation ... Dr. Roger (Feng) Luo as the new Vice President of Global Clinical Development. ... drug companies, Dr. Luo will now team with Dr. Li Xu, Chief Medical Officer, ...
(Date:2/28/2017)... ... February 28, 2017 , ... GigaGen ... from millions-diverse immune repertoires, today announced a strategic partnership with Trianni, Inc. ... to express human antibodies. The partnership will use GigaGen technology to discover immuno-oncology ...
Breaking Biology Technology:
(Date:2/21/2017)... February 21, 2017 Der weltweite ... wachsen. Nach einem Gespräch mit mehr als 50 Vertretern aus ... zu überwinden gilt, um diese Prognose zu realisieren. ... ... Mobilisierung der finanziellen Mittel für die Biobank, die Implementierung ...
(Date:2/13/2017)... 2017 Former 9/11 Commission border counsel and ... Janice Kephart of Identity Strategy Partners, LLP, today ... "Executive Order: Protecting the Nation From Foreign Terrorist ... "As President Trump,s ,Travel Ban, Executive Order gains ... banned the travel ban, it is important that our ...
(Date:2/8/2017)... 7, 2017  Aware, Inc. (NASDAQ: AWRE ), ... financial results for its quarter and year ended December 31, ... 2016 was $3.9 million compared to $6.9 million in the ... of 2016 was $0.6 million compared to $2.6 million in ... quarter of 2016 was $0.5 million, or $0.02 per diluted ...
Breaking Biology News(10 mins):